MYCN and neuroblastoma: One could argue the tumourigenic impact of the Aurora-A and -B kinases is exacerbated by MYCN-amplification, an assertion supported by work using the dual Aurora-A/B kinase inhibitor CCT137690 that solely demonstrated efficacy in MYCN-amplified neuroblastoma cell lines and in vivo [205].